论文部分内容阅读
与传统化疗相比,自体干细胞移植患者完全缓解(CR)、非常好的部分缓解(VGPR)、无进展生存期及总生存期均明显提高,已成为65岁以下初治多发性骨髓瘤患者一线治疗。新药沙利度胺、来那度胺和硼替佐米联合地塞米松用于移植前的诱导化疗、预处理和维持治疗,显示出良好疗效,已逐步取代传统化疗方案,在复发和进展患者中亦显示出明显的疗效。初步研究提示来那度胺和硼替佐米可克服不利遗传学异常影响。
Compared with traditional chemotherapy, patients with autologous stem cell transplantation complete remission (CR), very good partial response (VGPR), progression-free survival and overall survival were significantly improved, has become the first line of patients under the age of 65 with multiple myeloma treatment. New drugs thalidomide, lenalidomide and bortezomib in combination with dexamethasone for pre-transplant induction chemotherapy, pretreatment and maintenance therapy showed good efficacy and has gradually replaced the traditional chemotherapy regimen in patients with recurrent and advanced Also showed a significant effect. Preliminary studies suggest that lenalidomide and bortezomib can overcome adverse genetic effects.